B of A Securities Maintains Underperform on PTC Therapeutics, Raises Price Target to $43
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Tazeen Ahmad maintains an Underperform rating on PTC Therapeutics (NASDAQ:PTCT) and raises the price target from $36 to $43.
May 18, 2023 | 11:46 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
B of A Securities maintains an Underperform rating on PTC Therapeutics and raises the price target from $36 to $43.
The news directly mentions PTC Therapeutics (PTCT) and the updated price target by B of A Securities. While the price target has been raised, the Underperform rating remains unchanged, indicating that the analyst still expects the stock to underperform in the short term. This may not have a significant impact on the stock price, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100